Evaluation of inter-patient variability in the pharmacodynamic indices of warfarin.


Journal

Expert review of cardiovascular therapy
ISSN: 1744-8344
Titre abrégé: Expert Rev Cardiovasc Ther
Pays: England
ID NLM: 101182328

Informations de publication

Date de publication:
Nov 2020
Historique:
pubmed: 22 8 2020
medline: 5 1 2021
entrez: 22 8 2020
Statut: ppublish

Résumé

Warfarin exhibits huge inter-individual variability in therapeutic response. We assessed the extent and the factors affecting inter-individual variability in the anticoagulation control using pre-validated pharmacodynamic indices. Patients receiving warfarin for at least 6 months were recruited. CHA₂DS₂-VASc, HASBLED, SAMe-TT2R2 scores, warfarin sensitive index (WSI), log-INR variability, and warfarin composite measure (WCM) were assessed. National Institute for Health and Care Excellence (NICE) guideline was adhered for assessing the anticoagulation control using time in therapeutic range (TTR) (TTR < 65%-poor; and TTR ≥ 65%-good). Odds ratio [95% confidence interval] was the effect estimate measure. Eighty-seven (39.5%) of the patients were poorly anticoagulated. Those with lower HASBLED [OR: 0.3; 0.1, 0.6] and SAMe-TT2R2 scores [OR: 0.2; 0.04, 0.7] and higher CHA₂DS₂-VASc score [OR: 1.8; 1.1, 1.3] predicted good anticoagulation control. Thirty-five (15.9%) patients had high INR variability. Lower TTR, shorter duration of therapy, and higher WSI were observed in patients with high INR variability, and presence of drugs with potential interaction significantly predicted high INR variability. Significant numbers of our patients on warfarin had poor anticoagulation control and high INR variability. We have identified duration of therapy, CHA₂DS₂-VASc score, and WSI as reliable predictors for anticoagulation control and INR variability.

Identifiants

pubmed: 32820971
doi: 10.1080/14779072.2020.1814144
doi:

Substances chimiques

Anticoagulants 0
Warfarin 5Q7ZVV76EI

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

835-840

Auteurs

Kannan Sridharan (K)

Department of Pharmacology & Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University , Manama, Kingdom of Bahrain.

Rashed Al Banna (R)

Department of Cardiology, Salmaniya Medical Complex, Ministry of Health , Manama, Kingdom of Bahrain.

Ali Mohamed Qader (AM)

College of Medicine and Medical Sciences, Arabian Gulf University , Manama, Kingdom of Bahrain.

Aysha Husain (A)

Department of Cardiology, Salmaniya Medical Complex, Ministry of Health , Manama, Kingdom of Bahrain.
RCSI-Bahrain , Manama, Kingdom of Bahrain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH